Three years ago, a month’s supply of Wegovy cost more than many Americans’ mortgage payments. Today, you can get a starting dose for the price of a decent dinner out.

The GLP-1 weight-loss revolution has entered a new phase: the price war is here, and it’s reshaping both the pharmaceutical industry and millions of waistlines in the process.

From $1,600 to $149

When Novo Nordisk launched Wegovy in the U.S. in 2021, the list price exceeded $1,600 per month. Today, self-pay patients can obtain a starting dose for just $149. Eli Lilly’s Zepbound, which debuted at over $1,000 monthly in 2023, now starts at $299 for vials — and the company cut prices by another $50 to $100 in December.

For Ruth Gonzalez, a 56-year-old self-employed American, those cuts have been transformative. She initially scrimped on groceries and cancelled streaming subscriptions to afford Zepbound’s roughly $350 monthly cost. The medication brought her blood pressure back to normal within six weeks and helped her lose more than 40 pounds. December’s price reduction allowed her to afford a more powerful dose.

“For someone on a fixed budget, it is absolutely helpful,” Gonzalez told the BBC.

Why Prices Are Finally Falling

The economics of GLP-1 drugs have been unusual from the start. Unlike most medications, where insurance typically covers treatment, many U.S. health plans have refused to pay for weight-loss drugs specifically. That forced pharmaceutical companies to compete directly for patients paying out of pocket — behaving more like retailers than traditional drugmakers.

They launched direct-to-consumer websites, struck distribution deals with Walmart and Costco, and slashed prices to attract customers. In February, Novo Nordisk announced it would reduce list prices by up to 50% starting in 2027, bringing Wegovy to $675 monthly.

But an even more dramatic shift is unfolding in India, where Novo’s patent expired on Friday. At least a dozen large Indian drugmakers have rolled out generic versions at discounts of up to 80%. Sun Pharmaceutical is offering generic semaglutide for roughly 750 rupees ($8) per weekly injection — about 3,400 rupees ($37) monthly — compared to Novo’s Indian retail price of 8,800 to 10,000 rupees.

Natco Pharma went even further, pricing its vial formulation at 1,290 rupees ($14) per month. More than 50 generic brands are expected to launch this year.

Quality Questions Linger

The flood of cheaper alternatives raises an uncomfortable question: are all these drugs created equal?

GLP-1 drugs are peptide-based medicines requiring specialized manufacturing and cold-chain distribution — far more complex than typical generic pills. “Quality control for these large molecules is more difficult than for small molecules,” said Knud Jensen, a chemistry professor at the University of Copenhagen and president of the European Peptide Society. “The molecule that is given to patients has to be perfect.”

Indian manufacturers insist they’ve made significant quality improvements. Salil Kallianpur, an independent pharma consultant, noted that companies have recognized that compliance “can be converted into a very valuable moat.” But experts generally agree that Indian quality control is still catching up to European and American standards.

Dr. Rajiv Kovil, a Mumbai-based diabetologist, plans to wait for more evidence before switching patients from branded drugs. Nearly 50% of his patients could benefit from GLP-1 medications, he said, but only 5% currently use them — largely due to cost.

Who Gets Left Behind

Even with price cuts, access remains uneven. Shekinah Samayah-Thomas, 62, has been rationing her remaining Wegovy supply since California’s Medicaid program stopped covering it for weight loss in January. Despite having sleep apnea, her coverage requests have been denied.

Health advocates argue that market competition alone won’t solve the access problem. “Direct-to-consumer options today are serving as a short-term solution,” said Tracy Zvenyach of the Obesity Action Coalition. “But I do not want them to deter from the overall goals of general, standard coverage of treatments for obesity.”

The Trump administration’s decision to have Medicare begin covering GLP-1 drugs on a trial basis in July could prove more meaningful than any price war — potentially influencing private insurers to follow suit.

For now, though, patients who can afford the new lower prices are finally getting some relief. The gold rush days of weight-loss drugmaking may be ending. The race to the bottom has begun.

Sources